ClinicalTrials.gg
CompletedNCT02314299SPIOC-101Updated Oct 26, 2015

A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration

A Phase 1/2 interventional study of MTP-131 in Diabetic Macular Edema and Age-related Macular Degeneration, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-10-26.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Stealth BioTherapeutics Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 33 under way, 11 of them phase 3. Macular Edema · United States.

Enrollment
168th of 244
20 · median 45
Started
2014
with 14 others
Phase 1/2
31 of 276
3 open now
Registered
146th of 276
by date

Among the 276 studies in Macular Edema with a site in United States, this one is the 168th largest by enrollment of the 244 interventional ones that give a count, is one of 15 that started in 2014, is one of 31 in phase 1/2, and was the 146th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 276 studies in Macular Edema with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label, dose-escalation clinical study, enrolling 21 subjects in one of the two treatment groups to determine the effects of topical ocular administration of low dose or high dose MTP-131 given twice a day in subjects with Diabetic Macular Edema and Age-Related Macular Degeneration.

03

Conditions studied

  • Diabetic Macular Edema
  • Age-related Macular Degeneration

Browse trials for

Keywords

  • Macular edema
  • Macular degeneration
  • MTP-131
  • Ocuvia™
04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's enrollment of 20 is below the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • General:

    1. Adults aged ≥18 and ≤ 80 years
    2. Women of must have a negative urine pregnancy test at Baseline and agree to use a highly effective method of throughout the study and 60 days after the last dose of study drug.
  • DME Treatment Group:

    1. Central subfield thickness (CST) ≥325 microns as measured by spectral domain optical coherence tomography (SD-OCT) at Screening and Baseline Visits
    2. BCVA (ETDRS) no better than 20/25 in the study eye
    3. BCVA (ETDRS) no worse than 20/640 in either eye
  • AMD Treatment Group:

    1. Non-exudative, intermediate age-related macular degeneration defined as an eye(s) having extensive intermediate drusen (10 or more drusen 63μm - 124μm) or large drusen (1 or more ≥125 μm) with no evidence of advanced AMD (i.e., no choroidal neovascularization or macular atrophy)
    2. BCVA (ETDRS) no worse than 20/400 in either eye

Exclusion criteria

Exclusion Criteria:

  • General:

    1. Inability to self-administer eye drops
    2. Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve (for example deferoxamine, chloroquine/hydroxychloroquine [Plaquenil], tamoxifen, phenothiazines and ethambutol)
    3. Any medical condition that, in the opinion of the investigator, would preclude safe participation in the study or completion of all study requirements and examinations
    4. Have a glycosylated () ≥ 12%
  • Ocular Conditions:

    1. Any ocular condition in the study eye that in the opinion of the investigator would prevent improvement in visual acuity or successful completion of any study examination
    2. Ocular hypertension or glaucoma, dry eye, and any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops

      • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Low Dose Regimen

    MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye

    Drug: MTP-131

  • Experimental
    High Dose Regimen

    MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye

    Drug: MTP-131

Interventions

07

What researchers measure

Primary outcomes

  1. Incidence and severity of systemic and ocular adverse events

    Time frame: From Baseline to Day 28

  2. Change from Baseline in vital sign measurements

    Time frame: From Baseline to Day 28

  3. Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy study (ETDRS) scale

    Time frame: From Baseline to Day 28

  4. Change from Baseline in slit lamp examinations

    Time frame: From Baseline to Day 28

  5. Change from Baseline in intraocular pressure

    Time frame: From Baseline to Day 28

  6. Change from Baseline in dilated fundoscopic examinations

    Time frame: From Baseline to Day 28

  7. Change from Baseline in central subfield thickness

    Time frame: From Baseline to Day 28

Secondary outcomes

  1. Change in central subfield thickness

    Diabetic Macular Edema (DME) subjects only

    Time frame: From Baseline to Day 28

  2. Change from Baseline in widefield angiography

    Diabetic Macular Edema (DME) subjects only

    Time frame: From Baseline to Day 28

  3. Change from Baseline in fundus autofluorescence pattern including the occurrence of and aggregate size of areas of macular atrophy

    Age-Related Macular Degeneration (AMD) subjects only

    Time frame: From Baseline to Day 28

  4. Change from Baseline in best corrected visual acuity (BCVA) as measured with the early treatment diabetic retinopathy study (ETDRS) scale

    All subjects

    Time frame: From baseline to Day 28

08

Study locations

1 site
  • Boston, Massachusetts, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2014, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2014
First posted
Dec 11, 2014
Start
Nov 2014
Primary completionActual
May 2015
CompletionActual
Jun 2015
Results delay requested
Oct 2, 2015
Last update
Oct 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02314299
Responsible party
Sponsor
First posted
Dec 11, 2014
Start date
Nov 2014
Primary completion
May 2015
Completion
Jun 2015
Last update
Oct 26, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion